This site is intended for Healthcare Professionals only.

Supply disruption hits Pfizer’s Champix tablets

Date:

Share post:

Pfizer’s Champix (varenicline tartrate) 0.5mg and 1mg tablets are currently in short supply following disruption in the manufacturing of the drug.

The shortage of the smoking cessation drug might continue a bit longer, as Pfizer is trying to address the issue.

The company has not given a timeline to resolve the situation.

“We understand and regret the challenges that the situation poses and realise the importance of this medicine to healthcare professionals and patients,” Pfizer said in a statement.

The drug maker also encouraged patients to consult healthcare professionals to find an alternative option of Champix.

“We remain committed to supporting smokers in their quit attempts. However, until the Champix shortage is resolved, patients will need to consult with their healthcare professional to choose an alternative treatment option,” Pfizer added.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Haleon to close Maidenhead manufacturing site affecting 435 jobs

Despite the closure, Haleon will retain its presence in the UK with corporate offices in Weybridge and London Haleon,...

UK pharmacies cut prices for weight-loss drugs Wegovy, Mounjaro amidst escalating competition

Obesity experts raise concern that retail marketing of weight-loss drugs could trivialise their side-effects   British pharmacies and slimming...

MHRA says many online pharmacies are ‘unregulated’,’ illegal’, or ‘fraudulent’

MHRA's latest initiative aims to empower consumers in the fight against online pharmacy frauds The Medicines and Healthcare products...

MHRA outlines strategic approach to AI regulation in healthcare for patient safety

MHRA's strategic principles aim to foster innovation while upholding rigorous standards of patient safety and regulatory integrity In a...